LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
AutoGenomics announces the launch of a novel test for B-RAF mutations
News | 02. 24. 2010
AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has launched an expanded test panel to detect 17 B-RAF mutations for research use to enhance the understanding of B-RAF mutations.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.